Universal Decolonization Request: Appraising a Pre-Post Study Before Adoption
You are the CNS in a 28-bed MICU with 4 CLABSIs in 12 months against 1.2 predicted (SIR 3.3). At a staff meeting, two nurses who attended a national conference propose "daily chlorhexidine bathing plus nasal mupirocin for every patient" to reduce bloodstream infections. Their evidence is a single-center pre-post study in a 16-bed surgical ICU (n=412, 48% reduction, no randomization, no concurrent control). The nurse manager supports starting next month. Pharmacy estimates $21,000/year plus 0.3 FTE; supply chain needs 60 days. Current bundle audits show 71% chlorhexidine scrub adherence, 88% dressing integrity, and 64% daily line-necessity documentation.
1. Formulate the clinical question and appraise the evidence the staff brought, including what it can and cannot tell you.
Read the worked answer
PICO: In adult MICU patients with central venous catheters (P), does universal daily chlorhexidine bathing plus nasal mupirocin (I), compared with current practice of chlorhexidine-impregnated dressings and standard bathing (C), reduce primary bloodstream infections and CLABSI per 1,000 catheter-days (O)?
Appraisal of the cited study:
- Pre-post design cannot separate the intervention from secular trend, co-interventions, or a Hawthorne effect - staff who know they are being studied improve everything.
- Single center, small SICU (n=412) - limited external validity for a mixed MICU with different case mix and device days.
- Outcome definition and case ascertainment may have shifted; a 48% relative reduction from a low baseline is compatible with a handful of events.
- No reported balancing measures (mupirocin resistance, contact dermatitis, cost, adherence).
What the wider evidence base suggests (verify currency before citing):
- A large multicenter cluster-randomized ICU trial of universal decolonization versus screening-based or targeted approaches found universal decolonization reduced bloodstream isolates substantially - stronger support for the concept than the local pre-post study.
- However, the highest-yield intervention in a unit with 71% scrub adherence and 64% necessity review is almost certainly closing those process gaps first.
Bottom line: the evidence supports considering decolonization as an adjunct; it does not support skipping the compliance problem the audit already identifies.
2. What implementation design and measurement plan would you propose, and in what sequence?
Read the worked answer
Sequence matters: fix execution first, then add therapy.
Phase 1 (0–90 days) - maximize the existing bundle:
- Target the two weakest links: scrub adherence and daily necessity review.
- Interventions with known effect: just-in-time coaching, a two-person bathing checklist, line-necessity prompts at multidisciplinary rounds, and daily feedback of unit-level adherence.
- Measure with a run chart or SPC chart: adherence, catheter-days per 1,000 patient-days, CLABSI.
Phase 2 (90+ days) - pilot decolonization if CLABSI persists:
- Do not implement unit-wide on a fixed launch date. Run a time-limited pilot with a pre-specified protocol, eligibility criteria, and a written stop rule.
- Pre-specify measures before go-live:
- Outcome: CLABSI per 1,000 catheter-days; all-cause bloodstream infection.
- Process: bathing adherence, mupirocin adherence, protocol deviations.
- Balancing: mupirocin resistance on surveillance cultures, skin breakdown or contact dermatitis, cost per patient-day, nursing time.
- Use SPC methodology with annotated intervention dates rather than pre-post percentages.
- Align with infection prevention and pharmacy before purchase; run the proposal through the appropriate practice or quality committee.
Why this order: if adherence to the cheap, well-established bundle is 71%, spending $21,000/year on a new product before fixing it risks attributing improvement to the wrong thing - or masking a still-broken process.
3. How do you respond to the nurse manager's "start next month" timeline without shutting down staff enthusiasm?
Read the worked answer
Treat staff who bring evidence as an asset; redirect their energy into the appraisal and pilot, not the launch party.
Response:
- Validate the instinct - "You identified a real problem and brought literature. That's exactly what I want." Then sharpen it: "Help me pressure-test whether this is our highest-yield next step."
- Assign them real work - co-lead the adherence audit or the pilot protocol. Engaged clinicians who own the measurement are less invested in a foregone conclusion.
- Be transparent about the timeline and the reason - 60-day supply chain lead time is a fact; so is the committee review. Offer an interim win: a 30-day adherence sprint with weekly data feedback that starts now.
- Give the manager a decision path, not a no - "Here are the criteria that would trigger purchase; here's the date I'll bring the pilot data to committee."
- Name your binding constraint explicitly. If unit CLABSI is driven by necessity review and scrub technique, say so with the audit numbers rather than with opinion.
- Protect the relationship for the next proposal - write the decision rationale into the committee minutes so the reasoning survives staff turnover.